Tra­vere plans to lay off 20% of work­force as it fo­cus­es on full ap­proval for kid­ney dis­ease drug

Last year
People

J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

Last year
R&D
Pharma

Ex­clu­sive: Fund­ing for women’s health star­tups is up more than 300% over the last 5 years

Last year
Health Tech

Ex­clu­sive: Gary Glick’s Odyssey rais­es $101M Se­ries C as first im­munol­o­gy drugs ap­proach the clin­ic

Last year
Financing

A CAR-T ther­a­py in­vent­ed at Seat­tle Chil­dren’s was nev­er ap­proved for kids. Now the hos­pi­tal is launch­ing its own ...

Last year
Startups
Cell/Gene Tx

CRISPR repri­or­i­tizes CAR-T pipeline with cuts, ex­pands in­to au­toim­mune dis­ease as US de­ci­sion for exa-cel looms

Last year
R&D
Cell/Gene Tx

An­oth­er Flag­ship-found­ed biotech shut­ters as Ax­cel­la liq­ui­dates, end­ing long Covid plans

Last year
People
R&D

Sanofi forms drug dis­cov­ery pact with French start­up Aqemia en route to ‘AI at scale’ am­bi­tion

Last year
Startups
Deals

Al­to Neu­ro­science un­veils ef­fi­ca­cy sig­nal from PhI­Ia MDD tri­al with ma­chine learn­ing-iden­ti­fied bio­mark­er

Last year
R&D

23andMe said hack­ers ac­cessed over 5 mil­lion mem­bers’ an­ces­try in­fo

Last year
Health Tech

Roche's BTK in­hibitor put on par­tial hold over con­cerns about po­ten­tial liv­er in­jury

Last year
Pharma
FDA+

En­do hits the pool hall with Pey­ronie’s dis­ease pa­tients for lat­est cam­paign

Last year
Marketing

Fu­ji­film makes $200M man­u­fac­tur­ing in­vest­ment while No­var­tis pours $80M+ in­to Chi­na fa­cil­i­ty

Last year
Pharma
Manufacturing

Supreme Court weighs in on Pur­due Phar­ma's bank­rupt­cy, with an eye to­ward opi­oid vic­tims

Last year
Law

Health in­sur­ance mem­bers stand to lose out if Cigna and Hu­mana fi­nal­ize a megamerg­er, ex­perts say

Last year
Health Tech

House com­mit­tee in­ves­ti­gates FDA’s han­dling of com­mon nasal de­con­ges­tant as ef­fi­ca­cy ques­tions loom

Last year
Pharma
FDA+

Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

Last year
R&D

Ideaya part­ners with Gilead; Lil­ly ex­tends of­fer for Point; The­seus lets go of CEO, CMO

Last year
News Briefing

At­se­na touts one-year da­ta for con­gen­i­tal eye dis­ease ther­a­py as it seeks part­ner for piv­otal study

Last year
R&D
Cell/Gene Tx

Ab­bisko signs $70M up­front deal with Mer­ck KGaA for PhI­II can­cer drug

Last year
Deals
China

WuXi Bi­o­log­ics’ stock slides 24% as man­u­fac­tur­ing busi­ness slows amid biotech down­turn

Last year
Manufacturing

No­var­tis un­veils new brand iden­ti­ty af­ter San­doz spin­off

Last year
Pharma
Marketing

UCSF sci­en­tists aim to un­rav­el autism with brain organoids and AI

Last year
R&D
AI

Seis­mic rais­es $121M to en­ter im­munol­o­gy space spot­light­ed by ar­genx, Im­muno­vant and oth­ers

Last year
Financing
R&D
First page Previous page 236237238239240241242 Next page Last page
A service from the Financial Times